selumetinib,azacitidine
astrazeneca
['azacitidine,(-oral azaci),(-azacitidine oral)', '#mpn', 'award', 'selumetinib']
 , #meritawardrecipient #asco23, presents excellent study plan from ongoing phase-1 clinical trial assessing the outcomes of combinatorial treatment #selumetinib and #azacitidine for high-risk #mpn patients. 
Official Twitter of the NCI-designated University of Chicago Medicine Comprehensive Cancer Center, Chicago, IL USA. #WeAreNCIDesignated #NothingWillStopUs